C-Reveal Therapeutics is developing proprietary small molecule inhibitors of an immunomodulatory target identified and validated in Mark Cobbold's lab at Harvard/MGH. These inhibitors will disable a key novel tumor immune cloaking mechanism thus exposing the tumors to endogenous immune responses. C-Reveal’s drugs will be applicable to a broad spectrum of cancers and potentiate other cancer therapies such as checkpoint inhibitors, cancer vaccination, T Cell therapies and even traditional chemotherapy treatments.
View Top Employees from C-Reveal TherapeuticsWebsite | http://www.crev.bio |
Employees | 1 (1 on RocketReach) |
Founded | 2019 |
Industry | Biotechnology Research |
Looking for a particular C-Reveal Therapeutics employee's phone or email?
Thomas Haag is the Co-Founder, Chief Executive Officer of C-Reveal Therapeutics.
1 people are employed at C-Reveal Therapeutics.